The perioperative implications of tobacco, marijuana, and other inhaled toxins

International Anesthesiology Clinics

Volumn 49, Issue 1, 2011, Pages 103-118

  Bryson, Ethan O ^a   Frost, Elizabeth A M ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HEXANONE; 4 METHYL 2 PENTANONE; ACETONE; AMYL NITRATE; BENZENE; BUTANE; BUTYL ISOBUTYL NITRATE; CANNABIS; ETHER; HALOGENATED ETHER DERIVATIVE; HEXANE; NAPHTHALENE; NITRATE; NITROUS OXIDE; OCTANE; PROPANE; TOLUENE; TRICHLOROETHYLENE; TRICHLOROFLUOROMETHANE; UNCLASSIFIED DRUG; VOLATILE AGENT;

ARTICLE; CANNABIS SMOKING; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; HEMATOLOGIC DISEASE; METABOLIC DISORDER; NONHUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; TOBACCO; TREND STUDY;

ADMINISTRATION, INHALATION; CANNABIS; CARDIOVASCULAR DISEASES; EVOKED POTENTIALS; HUMANS; MARIJUANA ABUSE; NITROUS OXIDE; PERIOPERATIVE CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TOBACCO;

EID: 78751615280     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/AIA.0b013e3181dd4f53     Document Type: Article

References (48)

1. Bayer R, Kelly M. Tobacco control and free speech\an American dilemma. New Engl J Med. 2010;362:281-283.
2. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 2004.
3. Dube SR, Asman K, Malarcher A, et al. Cigarette smoking among adults and trends in smoking cessation United States 2008, Centers for Disease Control and Prevention. Morb Mortal Wkly Rep. 2009;58:1227-1232.
4. Shin HJ, Sohn HO, Han JH, et al. Effect of cigarette filters on the chemical composition and in vitro biological activity of cigarette mainstream smoke. Food Chem Toxicol. 2009;47:192-197.
5. Adams J, O'Mara-adams K, Hoffmann D. Toxic and carcinogenic agents in undiluted mainstream smoke and sidestream smoke of different types of cigarettes. Carcino-genesis. 1987;8:729-731.
6. US Department of health and human services. National Heart Lung and Blood Institute. Chronic Obstructive Pulmonary Disease. Bethesda, MD: HIH Publication No. 03-5229; 2003.
7. Sauerbeck LR, Homuung R, Moonaw CJ, et al. The effects of study participation in the familial intracranial aneurysm study on cigarette smoking. J Stroke Cerebrovasc Dis. 2008;17:370-372.
8. Woo D, Khoury J, Haverbusch MM, et al. Smoking and family history and risk of aneurismal subarachnoid hemorrhage. Neurology. 2009;72:69-72.
9. Warner MA, Diverti MR, Tinker JH, et al. Preoperative cessation of smoking and pulmonary complications in coronary artery bypass patients. Anesthesiology. 1984; 60:380-383.
10. Shi Y, Warner DO. Surgery as a teachable moment for smoking cessation. Anesthesiology. 2010;112:102-107.
11. Silvanus MT, Groeben H, Peters J. Corticosteroids and inhaled salbutamol in patients with reversible airway obstruction markedly decrease the incidence of bronchospasm after tracheal intubation. Anesthesiology. 2004;100:1047-1048.
12. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anesthesia. 2001;56:1059-1068.
13. Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998;352:1611-1616.
14. British Medical Association. Therapeutic Uses of Cannabis. London: Harwood Academic Publishers; 1997.
15. Sridhar KS, Raub WA, Weatherby NL. Possible role of marijuana smoking as a carcinogen in the development of lung cancer at an early age. J Psychoactive Drugs. 1994;26:285-288.
16. Benson M, Bentley AM. Lung disease induced by drug addiction. Thorax. 1995; 50:1125-1127.
17. Lawson TM, Rees A. Stroke and transient ischemic attacks in association with substance abuse in a young man. Postgrad Med. 1996;72:692-693.
18. Flisberg P, Paech MJ, Shah T, et al. Induction dose of propofol in patients using cannabis. Eur J Anaesthesiol. 2009;26:192-195.
19. Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol. 2000;5:37-46.
20. Smith WDA Under the Influence: MacMillan Pub Ltd Old Wokiing. 1982:20.
21. Priestley J. Observations on different kinds of air. In: Philosophical Transactions. Royal Society of London; 1772;62:210-224.
22. Davy H. Researches, Chemical and Philosophical: Chiefly Concerning Nitrous Oxide or Dephlogisticated Nitrous Air, and its Respiration. London: Biggs and Cottle forJJohnson; 1800:548-549.
23. Wright AJ. Davu comes to America: Woodhouse, Barton, and the nitrous oxide crossing. J Clin Anesth. 1995;7:347-355.
24. Wells A. A History of the Discovery of the Application of Nitrous Oxide Gas, Ether and Other Vapors to Surgical Operations. Hartford CT: J Gaylord Wells; 1847.
25. Blanton A. Nitrous oxide abuse: dentistry's unique addiction. J Tenn Dent Assoc. 2006;86:30-31.
26. Tymoczko D. The Nitrous Oxide Philosopher Atlantic Monthly. The Atlantic Monthly; 1996;277:5:93-101.
27. Gillman MA Nitrous Oxide, an opioid addictive agent. Review of the evidence. Am J Med. 1986;81:97-102.
28. Dzoljic MR, Haffmans J, Ruprehy J, et al. Decrease of beta endorphin in the brain of rats following nitrous oxide withdrawal. Drug Metabol Drug Interact. 1991;9: 139-148.
29. Yagiela JA. Health Hazards and nitrous oxide: a time for reappraisal. Anesth Prog. 1991;38:1-11.
30. Lin CY, Guo WY, Chen JT, et al. Neurotoxicity of nitrous oxide: multimodal evoked potentials in an abuser. Clin Toxicol (Phila). 2007;45:67-71.
31. Wu MS, Hsu YD, Lin JC, et al. Spinal myoclonus in subacute combined degeneration caused by nitrous oxide intoxication. Acta Neurol. 2007;16:102-105.
32. Cartner M, Sinnott M, Silburn P. Paralysis caused by "nagging". Med J Aust. 2007; 187:366-367.
33. Waters MF, Kang GA, Mazziotta JC, et al. Nitrous oxide inhalation as a cause of cervical myelopathy. Acta Neurol Scand. 2005;12:270-272.
34. Butzkueven H, King JO. Nitrous oxide myelopathy in an abuser of whipped cream bulbs. J Clin Neurosci. 2000;7:73-75.
35. Garbaz L, Mispelaere D, Boulemy M. Pneumothorax following recreational inhalation of nitrous oxide. Rev Mal Presp. 2007;24:622-624.
36. Hwang JC, Himel HN, Edlich RF. Frostbite of the face after recreational misuse of nitrous oxide'. Burns. 1996;22:152-153.
37. Kong JT, Schmiesing C. Concealed mothball abuse prior to anesthesia: mothballs, inhalants, and their management. Acta Anaesthesiol Scand. 2005;49:113-116.
38. Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. JAdolesc Health. 2001;28:170-180.
39. Perron BE, Howard MO, Vaughn MG, et al. Inhalant withdrawal as a clinically significant feature of inhalant dependence disorder. Med Hypotheses. 2009;73: 935-937.
40. Keriotis AA, Upadhyaya HP Inhalant dependence and withdrawal symptoms. J Am Acad Child Adolesc Psychiatry. 2000;39:679-680.
41. Shen YC. Treatment of inhalant dependence with lamotrigine. Prog Neuropsycho-pharmacol Biol Psychiatry. 2007;31:769-771.
42. Maclver BM. Abused inhalants enhance GABA-mediated synaptic inhibition. Neuropsychopharmacology. 2009;34:2296-2304.
43. Lopreato GF, Phelan R, Borghese CM, et al. Inhaled drugs of abuse enhance serotonin-3 receptor function. Drug Alcohol Depend. 2003;70:11-15.
44. Bieda MC, Su H, MacIver MB. Anesthetics discriminate between tonic and phasic gamma-aminobutyric acid receptors on hippocampal CA1 neurons. Anesth Analg. 2009;108:484-490.
45. Sicinski M, Kadam U. Monitoring of the anesthetic volatile agent may be impaired in hydrocarbon abusers. Anesthesia. 2002;57:510-511.
46. Bass M. Sudden sniffing death. JAMA. 1970;212:2075-2079.
47. Perron BE, Howard MO. Adolescent inhalant use, abuse and dependence. Addiction. 2009;104:1185-1192.
48. Broussard LA. The role of the laboratory in detecting inhalant abuse. Clin Lab Sci. 2000;13:205-209.